8-K: NewAmsterdam Pharma Announces Positive Phase 3 Trial Results for Obicetrapib and Ezetimibe Combination

NewAmsterdam Pharma's Phase 3 TANDEM trial demonstrated that a fixed-dose combination of obicetrapib and ezetimibe significantly reduced LDL-C levels in patients with high cardiovascular risk.

Summary

• NewAmsterdam Pharma announced positive topline results from its Phase 3 TANDEM clinical trial.
• The trial evaluated a fixed-dose combination of obicetrapib 10 mg and ezetimibe 10 mg in patients with heterozygous familial hypercholesterolemia (HeFH) and/or atherosclerotic cardiovascular disease (ASCVD).
• The study included patients whose LDL-C was not adequately controlled despite being on maximally tolerated lipid-lowering therapy.
• The TANDEM trial met all co-primary endpoints, showing a statistically significant reduction in LDL-C levels.
• The fixed-dose combination achieved a 48.6% reduction in LDL-C compared to placebo at day 84.
• The combination also showed significant reductions compared to ezetimibe and obicetrapib monotherapies.
• Over 60% of patients in the fixed-dose combination group experienced a greater than 50% decrease in LDL-C levels.
• Approximately 71%, 80%, and 90% of patients in the fixed-dose combination group achieved LDL-C levels of less than 55 mg/dl, 70 mg/dl, and 100 mg/dl, respectively.
• The fixed-dose combination was well-tolerated, with safety results comparable to placebo.
• The study involved 407 patients randomized across four arms: fixed-dose combination, obicetrapib monotherapy, ezetimibe monotherapy, and placebo.
• The mean baseline LDL-C for patients in the obicetrapib-ezetimibe arm was 97 mg/dL despite high intensity statin use in approximately 74% of patients.

Sentiment

Score: 9

Explanation: The document presents very positive results from a Phase 3 trial, with strong efficacy and safety data. The company's management is optimistic about the future, and the results are likely to be well-received by investors.

Positives

• The fixed-dose combination of obicetrapib and ezetimibe demonstrated a significant reduction in LDL-C levels.
• The combination therapy was well-tolerated with a safety profile similar to placebo.
• The trial met all co-primary endpoints, indicating a strong efficacy of the combination.
• A high percentage of patients achieved target LDL-C levels with the fixed-dose combination.
• The results support global regulatory filings for the fixed-dose combination.
• The study showed a synergistic effect of the combination, suggesting a benefit beyond convenience.

Negatives

• There were some study drug-related treatment emergent adverse events (TEAEs), although they were generally low.
• A small percentage of patients discontinued the study drug due to TEAEs.

Risks

• The company faces risks related to the approval of its product candidate and the timing of regulatory milestones.
• There are risks associated with commercializing the product candidate.
• The company's ability to negotiate and enter into definitive agreements on favorable terms is a risk.
• The impact of competing product candidates on the company's business is a risk.
• Intellectual property related claims are a potential risk.
• The company's ability to attract and retain qualified personnel is a risk.
• The ability to continue to source raw materials for its product candidate is a risk.
• Global economic and political conditions, including the Russia-Ukraine and Israel-Hamas conflicts, pose risks.

Future Outlook

The company expects these results to support global regulatory filings and believes the combination therapy will offer a simple, once-daily treatment capable of significantly reducing LDL-C and improving cardiovascular outcomes. They plan to present additional results at an upcoming medical conference and publish the data in a major medical journal.

Management Comments

• John Kastelein, M.D., Ph.D., FESC, Chief Scientific Officer of NewAmsterdam, stated that they observed clinically meaningful and statistically significant LDL-C lowering with the fixed-dose combination.
• Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam Pharma, said that the announcement represents a major achievement in their mission to bring a new and effective therapy to patients with dyslipidemia.
• Ashish Sarraju, M.D., Cardiovascular Medicine, Cleveland Clinic, noted that the results advance the understanding of potential new tools for lipid management for patients at high risk of cardiovascular disease.

Industry Context

The announcement is significant as it addresses the unmet need for effective LDL-C lowering therapies, particularly for patients who do not achieve target levels with existing treatments. The market for non-statin therapies is growing, and this combination therapy could be a strong contender.

Comparison to Industry Standards

• The results of the TANDEM trial are impressive when compared to existing therapies.
• While statins are the first-line treatment for high cholesterol, many patients do not reach their LDL-C goals with statins alone.
• Ezetimibe is a non-statin therapy that is often used in combination with statins, but the TANDEM trial shows that the combination of obicetrapib and ezetimibe is more effective than ezetimibe alone.
• PCSK9 inhibitors are another class of non-statin therapies that are very effective at lowering LDL-C, but they are injectable and more expensive than oral therapies.
• Bempedoic acid is another non-statin oral therapy, but the TANDEM trial results suggest that the obicetrapib and ezetimibe combination may be more effective.
• The TANDEM trial results are comparable to or better than some of the results seen in trials of other non-statin therapies, such as inclisiran, which is an injectable PCSK9 inhibitor.
• The fixed-dose combination of obicetrapib and ezetimibe has the potential to become a new standard of care for patients who need additional LDL-C lowering beyond statins.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical trial results.
• Patients with high cardiovascular risk may benefit from a new, effective treatment option.
• Physicians will have a new tool for managing patients with high LDL-C.
• The company's employees may be motivated by the positive results and the potential for commercial success.

Next Steps

• NewAmsterdam plans to present additional results from TANDEM at an upcoming medical conference.
• The company plans to publish the data in a major medical journal.
• The company will proceed with global regulatory filings for the fixed-dose combination.

Key Dates

Keywords

Obicetrapib, Ezetimibe, LDL-C, Cardiovascular Disease, HeFH, ASCVD, Lipid-Lowering Therapy, Clinical Trial, TANDEM, Cholesterol, Phase 3, Fixed-Dose Combination